# PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

> **NCT05543707** · PHASE2 · TERMINATED · sponsor: **Pardes Biosciences, Inc.** · enrollment: 242 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** PBI-0451 (Pomotrelvir)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05543707
- **Lead sponsor:** Pardes Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-21
- **Primary completion:** 2023-01-27
- **Final completion:** 2023-04-14
- **Target enrollment:** 242 (ACTUAL)
- **Why stopped:** Interim analysis concluded primary endpoint was not met
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05543707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05543707, "PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05543707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*